Abstract
Over the last several years a great deal of interest has been focused on the metabotropic glutamate receptors as potential targets for the treatment of a variety of disorders of the central nervous system. Recently, selective agonist or allosteric potentiators of mGluR4, one of the group III mGluRs, have been proposed as potential novel therapeutics for the palliative treatment of Parkinsons disease and some forms of epilepsy. mGluR4 stands out amongst the group III mGluRs due to its relatively restricted localization and apparent role in several key neuronal circuits. Work from a number of laboratories has led to the development of more selective tools for the study of mGluR4, as well as refined models of the structure and function of this receptor. In addition, a growing body of literature suggests that mGluR4 plays a key neuroprotective role in broad spectrum of neurodegenerative disorders. It is hoped that this increased understanding of the role of mGluR4 combined with more detailed structural information will spur the development of better pharmacological tools, and ultimately to novel clinical therapy.
Keywords: mglur, glutamate, parkinsons disease
Current Topics in Medicinal Chemistry
Title: Targeting the Metabotropic Glutamate Receptor mGluR4 for the Treatment of Diseases of the Central Nervous System
Volume: 5 Issue: 9
Author(s): Michael J. Marino, J. F. Hess and Nigel Liverton
Affiliation:
Keywords: mglur, glutamate, parkinsons disease
Abstract: Over the last several years a great deal of interest has been focused on the metabotropic glutamate receptors as potential targets for the treatment of a variety of disorders of the central nervous system. Recently, selective agonist or allosteric potentiators of mGluR4, one of the group III mGluRs, have been proposed as potential novel therapeutics for the palliative treatment of Parkinsons disease and some forms of epilepsy. mGluR4 stands out amongst the group III mGluRs due to its relatively restricted localization and apparent role in several key neuronal circuits. Work from a number of laboratories has led to the development of more selective tools for the study of mGluR4, as well as refined models of the structure and function of this receptor. In addition, a growing body of literature suggests that mGluR4 plays a key neuroprotective role in broad spectrum of neurodegenerative disorders. It is hoped that this increased understanding of the role of mGluR4 combined with more detailed structural information will spur the development of better pharmacological tools, and ultimately to novel clinical therapy.
Export Options
About this article
Cite this article as:
Marino J. Michael, Hess F. J. and Liverton Nigel, Targeting the Metabotropic Glutamate Receptor mGluR4 for the Treatment of Diseases of the Central Nervous System, Current Topics in Medicinal Chemistry 2005; 5 (9) . https://dx.doi.org/10.2174/1568026054750263
DOI https://dx.doi.org/10.2174/1568026054750263 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Feature Extraction and Classification of Epilepsy in Different Seizure Types: A Survey
Current Medical Imaging Polymeric Materials and Formulation Technologies for Modified-Release Tablet Development
Mini-Reviews in Medicinal Chemistry The Effect of Protein Restriction in the In Vitro Metabolism of Albendazole in Rats
Drug Metabolism Letters The Role of Melatonin in the Immuno-Neuro-Psychology of Mental Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Functional Roles of Benzothiazole Motif in Antiepileptic Drug Research
Mini-Reviews in Medicinal Chemistry Preface
Current Pharmaceutical Design Personalized Treatment of Obsessive-Compulsive Disorder: Radiology, EEG, Pharmacogenetics and Biochemistry
Current Pharmacogenomics and Personalized Medicine FDG-PET in the Evaluation of Brain Metabolic Changes Induced by Cognitive Stimulation in aMCI Subjects
Current Radiopharmaceuticals The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders: Autism Spectrum Disorders and Fragile X Syndrome
Current Neuropharmacology NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease
Current Neuropharmacology Minimizing AED Adverse Effects: Improving Quality of Life in the Interictal State in Epilepsy Care
Current Neuropharmacology The Prophylactic Use of Antiepileptic Drugs in Patients Scheduled for Neurosurgery
Current Pharmaceutical Design Disruption of Zinc Neuromodulation by Aß Oligomers : Therapeutic Implications
Current Pharmaceutical Design Neuroprotection for Ischemic Injury in the Immature Brain
Current Pediatric Reviews Targeting Oxidative Stress Component in the Therapeutics of Epilepsy
Current Topics in Medicinal Chemistry Fructose 1,6-Bisphosphate: A Summary of Its Cytoprotective Mechanism
Current Medicinal Chemistry Homocysteine in Neurological Disease: A Marker or a Cause?
CNS & Neurological Disorders - Drug Targets Cancer Nanotechnology: Recent Trends and Developments in Strategies for Targeting Cancer Cells to Improve Cancer Imaging and Treatment
Current Drug Metabolism Characterization of Single Nucleotide Polymorphisms of Cytochrome P450 in an Australian Deceased Sample
Current Drug Metabolism Modulators of Networks: Molecular Targets of Arterial Calcification Identified in Man and Mice
Current Pharmaceutical Design